Premium
Diagnosis of asthma and permitted use of inhaled β 2 ‐agonists in athletes
Author(s) -
Bonini S.,
Brusasco V.,
Carlsen K.H.,
Delgado L.,
Giacco S. D.,
Haahtela T.,
Rasi G.,
Cauwenberge P. B.
Publication year - 2004
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1046/j.1398-9995.2003.00355.x
Subject(s) - athletes , asthma , medicine , exercise induced asthma , population , inhaled corticosteroids , physical therapy , pediatrics , environmental health
The prevalence of asthma and bronchial hyperreactivity has been reported to be higher in athletes than in the general population. This has also been related to reported asthma in order to obtain permitted use of β 2 ‐agonists, whose assumption in athletes is ruled by anti‐doping regulations. The paper addresses the issue whether the recently established and evaluated rules of the International Olympic Committee on tests and procedures for diagnosis of asthma in athletes and permitted use of β 2 ‐agonists are consistent with an adequate diagnosis and management of asthma according to international guidelines.